Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease

Experimental and Molecular Pathology

Volumn 94, Issue 2, 2013, Pages 366-371

  Cimino, Patrick J ^a   Yang, Yue ^a   Li, Xianwu ^a   Hemingway, Jake F ^a   Cherne, Makenzie K ^a   Khademi, Shawn B ^a   Fukui, Yoshinori ^b   Montine, Kathleen S ^a   Montine, Thomas J ^a   Keene, C Dirk ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid beta; Innate immunity; Microglia; PGE2 receptor EP2

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; DEDICATOR OF CYTOKINESIS 2 PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION SIZE; CELL CULTURE; CELL DENSITY; CELL STRUCTURE; CONTROLLED STUDY; DOCK2 GENE; GENE EXPRESSION; GENOTYPE; HIPPOCAMPUS; HOMOZYGOSITY; IMMUNOPATHOGENESIS; IN VIVO STUDY; INNATE IMMUNITY; MICROGLIA; MOUSE; NONHUMAN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DINOPROSTONE; DISEASE MODELS, ANIMAL; GENOTYPE; GTPASE-ACTIVATING PROTEINS; IMMUNITY, INNATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, AMYLOID;

EID: 84873433241     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.01.002     Document Type: Article

References (49)

1. Lyketsos C.G., Breitner J.C., et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68:1800-1808. Adapt Research Group.
2. Ahmad A.S., Yun Y.T., Ahmad M., Maruyama T., Dore S. Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. Neurotoxicity Research 2008, 14:343-351.
3. Cimino P.J., Keene C.D., Breyer R.M., Montine K.S., Montine T.J. Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Current Medicinal Chemistry 2008, 15:1863-1869.
4. Cimino P.J., Sokal I., Leverenz J., Fukui Y., Montine T.J. DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain. American Journal of Pathology 2009, 175:1622-1630.
5. Cole G.M., Morihara T., Lim G.P., Yang F., Begum A., Frautschy S.A. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Annals of the New York Academy of Sciences 2004, 1035:68-84.
6. Echeverria V., Clerman A., Dore S. Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. European Journal of Neuroscience 2005, 22:2199-2206.
7. Farfara D., Trudler D., Segev-Amzaleg N., Galron R., Stein R., Frenkel D. gamma-Secretase component presenilin is important for microglia beta-amyloid clearance. Annals of Neurology 2011, 69:170-180.
8. Fukui Y., Hashimoto O., Sanui T., et al. Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 2001, 412:826-831.
9. Funk C.D., FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. Journal of Cardiovascular Pharmacology 2007, 50:470-479.
10. Gollmer K., Asperti-Boursin F., Tanaka Y., et al. CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood 2009, 114:580-588.
11. Gotoh K., Tanaka Y., Nishikimi A., et al. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. The Journal of Experimental Medicine 2010, 207:721-730.
12. Halle A., Hornung V., Petzold G.C., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nature Immunology 2008, 9:857-865.
13. Hickman S.E., Allison E.K., El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. Journal of Neuroscience 2008, 28:8354-8360.
14. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular Engineering 2001, 17:157-165.
15. Jin J., Shie F.S., Liu J., et al. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. Journal of Neuroinflammation 2007, 4:2.
16. Keene C.D., Chang R., Stephen C., et al. Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2. American Journal of Pathology 2009, 174:2300-2309.
17. Keene C.D., Chang R.C., Lopez-Yglesias A.H., et al. Suppressed accumulation of cerebral amyloid beta peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. American Journal of Pathology 2010, 177:346-354.
18. Konstantinopoulos P.A., Lehmann D.F. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. Journal of Clinical Pharmacology 2005, 45:742-750.
19. Lei Y., Liu C., Saito F., Fukui Y., Takahama Y. Role of DOCK2 and DOCK180 in fetal thymus colonization. European Journal of Immunology 2009, 39:2695-2702.
20. Liang X., Wang Q., Hand T., et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. Journal of Neuroscience 2005, 25:10180-10187.
21. Liang X., Wang Q., Shi J., et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Annals of Neurology 2008, 64:304-314.
22. Lim G.P., Yang F., Chu T., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. Journal of Neuroscience 2000, 20:5709-5714.
23. Lobsiger C.S., Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nature Neuroscience 2007, 10:1355-1360.
24. Manabe Y., Anrather J., Kawano T., et al. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Annals of Neurology 2004, 55:668-675.
25. Martin B.K., Szekely C., Brandt J., et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Archives of Neurology 2008, 65:896-905.
26. McGeer P.L., McGeer E.G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiology of Aging 2007, 28:639-647.
27. Meinert C.L., McCaffrey L.D., Breitner J.C. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimer's & Dementia 2009, 5:93-104.
28. Miller K.R., Streit W.J. The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biology 2007, 3:245-253.
29. Montine T.J., Milatovic D., Gupta R.C., Valyi-Nagy T., Morrow J.D., Breyer R.M. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. Journal of Neurochemistry 2002, 83:463-470.
30. Nishikimi A., Fukuhara H., Su W., et al. Sequential regulation of DOCK2 dynamics by two phospholipids during neutrophil chemotaxis. Science 2009, 324:384-387.
31. Quinn J.F., Bussiere J.R., Hammond R.S., et al. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiology of Aging 2007, 28:213-225.
32. Reed-Geaghan E.G., Reed Q.W., Cramer P.E., Landreth G.E. Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. Journal of Neuroscience 2010, 30:15369-15373.
33. Sanui T., Inayoshi A., Noda M., et al. DOCK2 is essential for antigen-induced translocation of TCR and lipid rafts, but not PKC-theta and LFA-1, in T cells. Immunity 2003, 19:119-129.
34. Savonenko A., Munoz P., Melnikova T., et al. Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Experimental Neurology 2009, 217:63-73.
35. Shie F.S., Breyer R.M., Montine T.J. Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. American Journal of Pathology 2005, 166:1163-1172.
36. Shie F.S., Montine K.S., Breyer R.M., Montine T.J. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathology 2005, 15:134-138.
37. Shie F.S., Montine K.S., Breyer R.M., Montine T.J. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 2005, 52:70-77.
38. Town T., Nikolic V., Tan J. The microglial "activation" continuum: from innate to adaptive responses. Journal of Neuroinflammation 2005, 2:24.
39. Town T., Laouar Y., Pittenger C., et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nature Medicine 2008, 14:681-687.
40. West M.J. New stereological methods for counting neurons. Neurobiology of Aging 1993, 14:275-285.
41. Woltjer R.L., Cimino P.J., Boutte A.M., et al. Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. The FASEB Journal 2005, 19:1923-1925.
42. Wu L., Wang Q., Liang X., Andreasson K. Divergent effects of prostaglandin receptor signaling on neuronal survival. Neuroscience Letters 2007, 421:253-258.
43. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nature Medicine 2006, 12:1005-1015.
44. Xiang Z., Ho L., Yemul S., et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expression 2002, 10:271-278.
45. Yang W., Woltjer R.L., Sokal I., et al. Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. American Journal of Pathology 2007, 171:993-1002.
46. Yu Y., Fan J., Chen X.S., et al. Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nature Medicine 2006, 12:699-704.
47. Yu Y., Fan J., Hui Y., et al. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. Journal of Biological Chemistry 2007, 282:1498-1506.
48. Zhu Y., Hou H., Rezai-Zadeh K., et al. CD45 deficiency drives amyloid-beta peptide oligomers and neuronal loss in Alzheimer's disease mice. Journal of Neuroscience 2011, 31:1355-1365.
49. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends in Neurosciences 2006, 29:518-527.